Tower Research Capital (TRC)’s Context Therapeutics CNTX Stock Holding History
Bought
Maintained
Sold
Other funds holding CNTX
Tower Research Capital (TRC)'s CNTX Position: Q3 2026 in Review
Tower Research Capital (TRC) reduced its Context Therapeutics (CNTX) stake by 13% in Q3 2026, selling an estimated $1.89K and leaving 25,495 shares worth $7.66K. The position accounts for ﹤0.01% of the portfolio, ranked #4456.
Tower Research Capital (TRC) first reported a position in CNTX in Q4 2021 and has held it in 18 quarters since. The position peaked at $16.2K in Q2 2026. 87 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.
- Tower Research Capital (TRC) held 25,495 shares of Context Therapeutics worth $7.66K as of Q3 2026.
- Tower Research Capital (TRC) sold 3,836 Context Therapeutics shares in Q3 2026, an estimated $1.89K.
- Context Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4456 holding.
- Tower Research Capital (TRC) first reported a position in Context Therapeutics in Q4 2021 and has held it in 18 quarters since.
- Tower Research Capital (TRC)'s Context Therapeutics position peaked at $16.2K in Q2 2026.
- 87 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.